DUBLIN, IRELAND--(MARKET WIRE)--Jul 19, 2006 -- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Medical Technology Company focused on the Woundcare, Oralcare and Cardiovascular Health markets today announces the establishment of a global mutually exclusive joint venture technology and business development partnership (JV) with current nanotechnology R&D partners Elmarco.
